Actually, the author appears to have an agenda.

"Furthermore, Afrezza wasn’t the only diabetic medication whose market potential was rightfully stunted by the FDA in the last year."

Rightfully stunted by the FDA???

Let's see:

Avandia - associated with heart attack, stroke, death

Actos - bladder cancer

dapagliflozin - breast cancer, bladder cancer

Afrezza - ????

Of course did anyone notice that the author is a lawyer and his blog is called "Injury Board"?